Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.10.12
Views: 3800
Rating:

Dr Thomas Bachelot – Centre Leon Berard, Lyon

Dr Thomas Bachelot talks with ecancer at the 2012 ESMO meeting about the LANDSCAPE study, which assessed the potential efficacy of combination therapy with capecitabine and lapatinib.

 

The study’s goal was to administer the combination as front line treatment in patients with HER 2 metastatic breast cancer in order to delay radiotherapy.

 

This treatment can also treat metastases to the brain and other systemic diseases.

 

Of the 45 patients in the study, 38 had either stabilised or partial response. The median time was 7.9 months to delay radiotherapy. This delay is very important for patients as it potentially extends survival without toxicity.

 

Filming supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation